Cookie policy: This site uses cookies (small files stored on your computer) to simplify and improve your experience of this website. Cookies are small text files stored on the device you are using to access this website. For more information please take a look at our terms and conditions. Some parts of the site may not work properly if you choose not to accept cookies.

Join

Subscribe or Register

Existing user? Login

Notification

NICE recommends idelalisib for chronic lymphocytic leukaemia

The National Institute for Health and Care Excellence has published final guidance that recommends idelalisib (Zydelig; Gilead) when used in combination with another cancer treatment rituximab to treat adults with chronic lymphocytic leukaemia who have one of two genetic changes (17p deletion or TP53 mutation) and have not received any other treatment. The guidance stipulates that idelalisib can only be prescribed if the company provides the drug at a pre-agreed discounted rate.

Citation: The Pharmaceutical Journal DOI: 10.1211/PJ.2015.20069657

Have your say

For commenting, please login or register as a user and agree to our Community Guidelines. You will be re-directed back to this page where you will have the ability to comment.

Recommended from Pharmaceutical Press

  • Introduction to Renal Therapeutics

    Introduction to Renal Therapeutics

    Introduction to Renal Therapeutics covers all aspects of drug use in renal failure. Shows the role of the pharmacist in patient care for chronic kidney disease.

    £38.00Buy now

Search an extensive range of the world’s most trusted resources

Powered by MedicinesComplete
  • Print
  • Share
  • Comment
  • Save
  • Print Friendly Version of this pagePrint Get a PDF version of this webpagePDF

Jobs you might like

Newsletter Sign-up

Want to keep up with the latest news, comment and CPD articles in pharmacy and science? Subscribe to our free alerts.